Surrozen, Inc.

NASDAQ•SRZN

CEO: Mr. Craig C. Parker M.B.A.

板块: Healthcare

行业: Biotechnology

上市日期: 2021-01-11

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

联系方式

171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, 94080, United States

650-489-9000

www.surrozen.com

市值

$244.63M

市盈率 (TTM)

-2.8

19.7

股息率

52周最高

$29.60

52周最低

$5.90

52周范围

96%

排名43Top 50.7%

3.8

F-Score

改良版 Piotroski 分析

基于 6 年期基本面

疲弱 • 3.8 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2020-2025

财务仪表盘

Q3 2025 数据

营业收入

$983.00K-90.17%

近4季度走势

每股收益

-$8.36+1800.00%

近4季度走势

自由现金流

-$9.06M+34.24%

近4季度走势

2025 Q3 财报亮点

核心亮点

Significant 2025 PIPE Funding Nine months financing provided 71.3M USD, primarily from the March 2025 PIPE proceeds, bolstering capital resources.

Related Party Revenue Surge Research service revenue reached 2.9M USD for nine months, driven by the TCGFB collaboration agreement executed in 2024.

Strong Cash Position Maintained Cash and equivalents totaled 81.3M USD as of September 30, 2025, supporting operations for at least 12 months.

SZN-8141 IND Filing Expected The company anticipates filing the Investigational New Drug application for SZN-8141 during 2026 to commence clinical studies.

关注风险

Net Loss Widened Significantly Nine month net loss increased 66% to 58.9M USD in 2025, driven by higher R&D expenses and non-cash charges.

Operating Expenses Increased Total operating expenses rose 20% to 32.4M USD for nine months, primarily due to 29% growth in R&D spending.

TCGFB Collaboration Terminated Research Collaboration with TCGFB terminated effective November 2025, eliminating future related party revenue streams.

Future Capital Requirements High Expect continued losses and substantial additional capital needed to advance pipeline through clinical development and regulatory submissions.

前瞻展望

Advance Key Ophthalmology Candidates Strategy focuses on advancing SZN-8141 and SZN-8143 through IND filing and into Phase 1 clinical studies in 2026.

Discontinued SZN-043 Development Development of SZN-043 halted in Q1 2025 due to insufficient early signal of clinical benefit for severe alcohol associated hepatitis.

2025 ATM Program Inactive The 50.0M USD At-the-Market program established in August 2025 has not yet resulted in any common stock sales as of period end.

Maintain Intellectual Property Rights Continued focus on securing and defending patent rights for Wnt platform and product candidates against potential third-party challenges.

同行对比

营业收入 (TTM)

AGEN

$106.83M

-33.4%

MGX

$30.91M

-43.9%

ZNTL

$26.87M

-33.8%

毛利率 (最新季度)

SRZN

100.0%

+0.0pp

IRD

99.6%

-0.4pp

MGX

84.7%

-15.3pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
ARMP	$422.68M	-9.0	70.3%	198.5%
GLSI	$374.07M	-18.9	-1042.8%	0.0%
NAUT	$330.92M	-5.6	-33.6%	15.7%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

14.5%

稳定增长

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

25%

现金流需要关注

深度研究

下次财报:2026年3月19日

每股收益:-$1.29

营业收入:$661.00K

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据